Ozempic® / Wegovy® / Rybelsus®
Semaglutide (Injection & Oral)
Version 2025-04 · Last reviewed April 1, 2025 · Methodology
List Price
$969
With Insurance
$25-100
FDA Black Box Warning
THYROID C-CELL TUMORS
Causes tumors in rats at human doses. Unknown human risk.
Strict Contraindications
How It Works
Semaglutide mimics GLP-1, a natural gut hormone released after eating. It simultaneously slows digestion, suppresses appetite signals in the brain, and forces the pancreas to release insulin only when blood sugar is elevated.
Why the side effects happen
Nausea and vomiting come directly from slowing gastric emptying — the same mechanism that reduces hunger. As the body adapts over 4–8 weeks, these effects diminish. The weekly injection format was engineered to maintain stable blood levels and reduce peak-dose side effects seen with daily injections.
When Will I Feel It?
Appetite reduction begins within days; meaningful weight loss builds over months. Most people reach maximum effect around 9–12 months.
Reduced appetite and earlier fullness. Nausea and mild GI upset are common — this is the drug working as intended.
Blood glucose control improving. Most people lose 2–5% of body weight during this phase.
Accelerated weight loss. Average loss in SUSTAIN trial: ~6–8% body weight by week 40.
Maximum weight loss plateau. SEMAGLUTIDE STEP trials showed 14–15% average weight loss at 68 weeks with lifestyle counseling.
Adherence Note
Stopping Ozempic causes weight regain in most patients within 12 weeks — the STEP 4 trial showed full regain within 1 year of stopping. This is a chronic medication for a chronic condition, not a short course.
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Common Side Effects
While taking this medication, you may experience the following common side effects. We've included tips on how to manage them.
Nausea
20%Eat smaller portions and avoid greasy foods
Diarrhea
15%Stay hydrated; usually improves after first weeks
Vomiting
10%Take injection with food; avoid large meals
Constipation
11%Increase fiber and water intake
Stomach pain / cramping
9%Eat slowly and avoid high-fat foods
Decreased appetite
30%+Intentional; ensure adequate nutrition
Fatigue / tiredness
8%Usually mild; monitor blood sugar levels
Headache
7%Drink plenty of water; may improve with time
Injection site reaction
5%Rotate injection sites each week
Belching / indigestion
6%Avoid carbonated drinks and eat slowly
Serious Adverse Effects
- • Pancreatitis (<1%)
- • Kidney failure
- • Gallbladder disease
- • Vision changes (diabetic retinopathy)
- • Allergic reaction
- • Thyroid tumors (see Black Box)
Drug Interactions
Major Interactions (Avoid)
Moderate Interactions (Caution)
Food Interactions
When to Contact Your Doctor
This medication requires ongoing medical supervision. The following situations warrant a prompt conversation with your prescribing physician — do not wait for your next scheduled appointment.
Contact soon if you notice
- Pancreatitis
- Kidney failure
- Gallbladder disease
- Vision changes (diabetic retinopathy)
- Rising blood sugar above your target range
Also discuss if you want to
- Review whether this medication is still appropriate for you
- Consider dosage adjustments based on response
- Explore lifestyle or non-drug alternatives
- Understand stopping or tapering options
- Plan monitoring labs and follow-up
In the US, call 911 or go to the nearest emergency room for severe symptoms. Poison Control: 1-800-222-1222.
Special Populations
Safety classifications for specific groups — discuss with your provider before use.
Stop 2 months before pregnancy. Fetal harm in animals.
Unknown if in milk. Avoid.
Menopause accelerates insulin resistance and shifts fat toward the abdomen — the same pattern GLP-1 drugs target. Some of this metabolic change is driven by the drop in estrogen, not lifestyle alone. Before starting a GLP-1 for weight gain that began at menopause, ask your doctor whether hormonal changes are the primary driver.
No data under 18
Watch for dehydration
Monitor kidney function
FDA Adverse Event Reports
Patient-filed reports from the FDA FAERS database · refreshed daily
Community Reports
User-reported experiences — anonymous & anecdotal
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Metabolic & Lifestyle Alternatives
Metabolic Root-Cause Alternatives
Ketogenic diets have matched or exceeded Ozempic's HbA1c reduction in RCTs — while simultaneously improving lipid profiles. Virta Health's 2-year trial showed 53.5% T2D remission with no GLP-1 required. The driver of T2D is not fat intake — it is excess carbohydrate load triggering hyperinsulinemia and de novo lipogenesis.
Important context: Evidence quality varies across these approaches. Some are well-studied with randomized controlled trial data; others are based on observational or smaller studies. These interventions are not guaranteed to replace medication for all patients. Discuss with your doctor whether any of these are appropriate for your clinical situation.
Ketogenic Diet (<20g net carbs/day)
Eliminates the glucose/insulin burden driving beta-cell exhaustion and insulin resistance
HbA1c -1.3% sustained at 2 years; triglycerides down 40–50%; HDL up; LDL shifts to large buoyant (less atherogenic) particles. 94% of Virta participants reduced or eliminated diabetes medications.
Time-Restricted Eating (16:8 or OMAD)
Compresses the insulin-elevated window, restoring metabolic flexibility
Improves fasting insulin, HbA1c, and visceral fat independently of caloric restriction. Pairs especially well with low-carb.
Resistance Training (3×/week)
Heavy compound movements — squat, deadlift, press
Increases GLUT4 transporter density in muscle; glucose disposal increases 48%; HbA1c improves independently of weight loss; reduces visceral adipose tissue.
Omega-3 EPA/DHA (2–4g/day)
Suppresses hepatic de novo lipogenesis; improves insulin signaling
Reduces triglycerides 25–50%; reduces hepatic fat; improves insulin sensitivity. Addresses the lipid imbalance that often accompanies T2D.
Berberine (500mg 3×/day)
Activates AMPK — mimics metformin pathway
Multiple RCTs: HbA1c reduction equivalent to metformin; also lowers LDL and triglycerides. Available OTC without a prescription.
How It Compares
Ozempic (weekly injection) vs. Mounjaro/Zepbound (tirzepatide, dual GLP-1/GIP) — tirzepatide shows 20–22% weight loss vs. 14–15% for semaglutide, at similar cost
Strengths
- Once-weekly injection
- Strong cardiovascular outcomes data (SUSTAIN-6)
- Oral semaglutide (Rybelsus) option exists
- Most studied GLP-1 agonist globally
Weaknesses
- $1,000+/month without insurance
- Must continue indefinitely to maintain benefits
- Not all patients respond
Clinically Preferred Alternatives
Global Prescribing & Pricing
US prescribes GLP-1 drugs at 6–7x the rate of Europe
United States
$969/mo
12% of T2D patients on GLP-1 — highest globally
No lifestyle prerequisite required before prescribing
Varies by insurance plan; often denied
France
~$60/mo
1.8% of T2D patients — 6.7× lower than US
6 months mandatory nutrition counseling required first — funded by France's sugar beverage tax (taxe soda, €550M/year)
Fully covered by Sécurité Sociale after lifestyle program
United Kingdom
~$92/mo
2% of T2D patients — NICE restricts to severe cases
BMI ≥35 plus completion of structured lifestyle program required
Covered by NHS with strict criteria
Japan
~$54/mo
3% of T2D patients — lower-dose protocols
Maximum 0.5mg dose standard; comprehensive dietary assessment required
Covered by JHIS with criteria
Denmark
~$120/mo
3.5% — home of Novo Nordisk, still limits use
6-month supervised lifestyle intervention required and documented before approval
Covered with lifestyle compliance
France's sugar beverage tax (taxe soda, 2012) generates €550M/year, funding the mandatory nutrition counseling that replaces drug prescriptions for most patients. The same Ozempic pen costs $969/month in the US and ~$60 in France — and France requires patients to earn it through 6 months of documented nutrition work first.
Clinical Trials & Funding
Understanding who funds research helps contextualize results. Industry-funded trials are not automatically invalid — they undergo the same FDA review — but declared conflicts and sponsor effects are worth knowing. All linked trials can be verified on ClinicalTrials.gov.
Funding Sources
STEP trials and most published semaglutide research were funded by Novo Nordisk, which reported approximately $38.6B in semaglutide revenue in 2023. Lead investigators received advisory board fees, consulting payments, and travel support from Novo Nordisk and other pharmaceutical companies.
Declared Conflicts of Interest
Key opinion leaders in obesity and diabetes research receive consulting fees ranging $50k-500k+ annually from GLP-1 manufacturers. American Diabetes Association receives millions in pharmaceutical funding. Most major review articles and clinical practice guidelines authored by researchers with declared pharmaceutical conflicts of interest. Marketing budget for GLP-1 drugs exceeds $3B+ annually.
Key Efficacy Results
Expected HbA1c reduction: −1.5% to −1.8% from baseline (SUSTAIN trials, 0.5–2mg). Weight loss: −9–14 lbs. Wegovy (2.4mg/wk): −14.9% body weight (STEP-1). Lifestyle comparison: dietary intervention alone reduces diabetes risk by 58% (DPP trial). Oral semaglutide (OW3 9mg): −1.5–1.7% HbA1c in phase 3 trials.
Referenced Studies
Each study carries a Cochrane RoB-2 risk-of-bias badge — tap the badge for details.
Evidence & Transparency
Cochrane RoB-2 (Risk of Bias)
Badges reflect an editorial assessment using Cochrane's RoB-2 tool domains: randomization, intervention deviation, missing data, outcome measurement, and selective reporting. These are not certified Cochrane reviews. Learn more ↗
CMS Open Payments
Manufacturer payment disclosures are reported via the CMS Sunshine Act. Disclosure is legally required and does not imply bias or misconduct. Language uses "may," "suggests," or "appears" — never definitive clinical claims. CMS Open Payments ↗
Live Clinical Trials
Live from ClinicalTrials.gov · refreshed every 4 hours
Currently enrolling, active, and recently completed studies involving Semaglutide (Injection & Oral). Data is pulled directly from the U.S. National Library of Medicine.
Recent Research
Live from PubMed · peer-reviewed literature · refreshed every 4 hours
Most recently indexed clinical trials and systematic reviews mentioning Semaglutide (Injection & Oral) in PubMed.
Source Documentation
Structured citations for referenced clinical trials
Each referenced trial is listed with its registry ID, funding source, and bias assessment. Use the copy button to generate a formatted citation.
| Trial | Registry ID | Cite |
|---|---|---|
| SUSTAIN-1 | NCT02054897 | |
| SUSTAIN-2 | NCT01930188 | |
| STEP 1 (Novo) | NCT03548935 | |
| STEP 4 (Novo) | NCT03548987 | |
| STEP 5 (Novo) | NCT03693430 | |
| SELECT (Novo) | NCT03574597 |
Bias ratings use Cochrane RoB-2 methodology. Editorial assessment — not a certified Cochrane review.
Our MethodologyMedical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Stopping This Medication Safely
Abrupt discontinuation causes rapid blood sugar rebound, significant weight regain, and GI side effects as GLP-1 effects reverse within days.
What Published Research Shows About Stopping This Medication
This summarizes what published research documents — it is not personal medical advice. Any changes to your medication require discussion with your prescribing physician.
- ·Research supports building a lifestyle foundation (low-glycemic diet, exercise) before stopping
- ·Published tapering schedules describe dose reduction of 50% for 4 weeks before stopping (e.g., 1mg → 0.5mg)
- ·Research recommends monitoring fasting blood glucose weekly during and after stopping
- ·Clinical guidelines suggest rechecking HbA1c at 3 months after stopping
Warning Symptoms — Contact Your Doctor If You Experience:
- Rising blood sugar above your target range
- Rapid weight gain (>5 lbs in 2 weeks)
- Increased hunger and cravings
- Worsening HbA1c at follow-up
Never change or stop a medication without consulting your prescribing physician.
Questions for Your Doctor
Questions to Ask
- 1.Should I try diet changes first?
- 2.What are my A1C goals?
- 3.Are there lower-cost alternatives?
- 4.How long will I need to take this?
Lab Tests to Request
- HbA1c
- Kidney function (eGFR)
- Fasting glucose
- Thyroid (TSH)
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Frequently Asked Questions About Ozempic® / Wegovy® / Rybelsus®
- What is Ozempic® / Wegovy® / Rybelsus® used for?
- Ozempic® / Wegovy® / Rybelsus® (Semaglutide (Injection & Oral)) is a GLP-1 Receptor Agonist manufactured by Novo Nordisk. FDA-approved indications include: Type 2 diabetes; CV risk reduction in T2D; Kidney disease progression.
- What are the common side effects of Ozempic® / Wegovy® / Rybelsus®?
- Common side effects of Ozempic® / Wegovy® / Rybelsus® include: Nausea (20%); Diarrhea (15%); Vomiting (10%); Constipation (11%); Stomach pain / cramping (9%).
- How much does Ozempic® / Wegovy® / Rybelsus® cost?
- Ozempic® / Wegovy® / Rybelsus® list price is approximately $969. With insurance it typically costs $25-100; without insurance approximately $450-550.
- Who funded the clinical trials for Ozempic® / Wegovy® / Rybelsus®?
- STEP trials and most published semaglutide research were funded by Novo Nordisk, which reported approximately $38.6B in semaglutide revenue in 2023. Lead investigators received advisory board fees, consulting payments, and travel support from Novo Nordisk and other pharmaceutical companies.
- How strong is the clinical evidence for Ozempic® / Wegovy® / Rybelsus®?
- Key studies: SUSTAIN-1 through SUSTAIN-10, PIONEER, SELECT, STEP program. Expected HbA1c reduction: −1.5% to −1.8% from baseline (SUSTAIN trials, 0.5–2mg). Weight loss: −9–14 lbs. Wegovy (2.4mg/wk): −14.9% body weight (STEP-1). Lifestyle comparison: dietary intervention alone reduces diabetes risk by 58% (DPP trial). Oral semaglutide (OW3 9mg): −1.5–1.7% HbA1c in phase 3 trials. Potential conflicts of interest: Key opinion leaders in obesity and diabetes research receive consulting fees ranging $50k-500k+ annually from GLP-1 manufacturers. American Diabetes Association receives millions in pharmaceutical fun.
- Are there non-drug alternatives to Ozempic® / Wegovy® / Rybelsus®?
- Ketogenic diets have matched or exceeded Ozempic's HbA1c reduction in RCTs — while simultaneously improving lipid profiles. Virta Health's 2-year trial showed 53.5% T2D remission with no GLP-1 required. The driver of T2D is not fat intake — it is excess carbohydrate load triggering hyperinsulinemia See the Alternatives tab for full details.
Get notified when we update Ozempic® / Wegovy® / Rybelsus®
We'll email you when new evidence, safety updates, or alternatives are added.
No spam. Unsubscribe anytime.